参考文献/References:
[1] Merke DP,Auchus RJ.Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency[J].N Engl J Med,2020,383(13):1248-1261.DOI:10.1056/NEJMra1909786.
[2] Gau M,Konishi K,Takasawa K, et al.The progression of salt-wasting and the body weight change during the first 2 weeks of life in classical 21-hydroxylase deficiency patients[J].Clin Endocrinol(Oxf),2021,94(2):229-236.DOI:10.1111/cen.14347.
[3] 中华医学会儿科分会罕见病学组,中国医师协会医学遗传医师分会,中国妇幼保健协会出生缺陷防止与分子遗传分会,等.21羟化酶缺陷导致的先天性肾上腺皮质增生症的实验室诊断共识[J].中华医学遗传学杂志,2023,40(7):769-780.DOI:10.3760/cma.j.cn511374-20230330-00178.
[4] Bonfig W,Bechtold S,Schmidt H,et al.Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment:deceleration of growth velocity during puberty[J].J Clin Endocrinol Metab,2007,92(5):1635-1639.DOI:10.1210/jc.2006-2109.
[5] Melin J,Parra-Guillen ZP,Michelet R,et al.Pharmacokinetic/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia[J].J Clin Endocrinol Metab,2020,105(3):dgaa071.DOI:10.1210/clinem/dgaa071.
[6] Dubinski I,Bechtold Dalla-Pozza S,Bidlingmaier M,et al.Reverse circadian glucocorticoid treatment in prepubertal children with congenital adrenal hyperplasia[J].J Pediatr Endocrinol Metab,2021,34(12):1543-1548.DOI:10.1515/jpem-2021-0540.
[7] Cera G,Locantore P,Novizio R,et al.Pregnancy and prenatal management of congenital adrenal hyperplasia[J].J Clin Med,2022,11(20):6156.DOI:10.3390/jcm11206156.
[8] Nowotny H,Neumann U,Tardy-Guidollet V,et al.Prenatal dexamethasone treatment for classic 21-hydroxylase defificiency in Europe[J].Eur J Endocrinol,2022,186(5):K17-K24.DOI:10.1530/EJE-21-0554.
[9] Lajic S,Karlsson L,Nordenström A.Prenatal treatment of congenital adrenal hyperplasia:Long-Term effects of excess glucocorticoid exposure[J].Horm Res Paediatr,2018,89(5):362-371.DOI:10.1159/000485100.
[10] Stachanow V,Neumann U,Blankenstein O,et al.Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling[J].Eur J Endocrinol,2021,185(3),365-374.DOI:10.1530/EJE-21-0395.
[11] Claahsen-van der Grinten HL,Speiser PW,Ahmed SF,et al.Congenital adrenal hyperplasia-current insights in pathophysiology,diagnostics,and management[J].Endocr Rev,2022,43(1):91-159.DOI:10.1210/endrev/bnab016.
[12] Speiser PW,Arlt W,Auchus RJ,et al.Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2018,103(11):4043-4088.DOI:10.1210/jc.2018-01865.
[13] Livadas S,Bothou C.Management of the female with non-classical congenital adrenal hyperplasia(NCCAH):a patient-oriented approach[J].Front Endocrinol(Lausanne),2019,10:366.DOI:10.3389/fendo.2019.00366.
[14] Auchus RJ,Arlt W.Approach to the patient:the adult with congenital adrenal hyperplasia[J].J Clin Endocrinol Metab,2013,98(7):2645-2655.DOI:10.1210/jc.2013-1440.
[15] Jiang S,Kuang Y.The cycle characteristics and outcomes of infertile nonclassic 21-Hydroxylase deficiency patients undergoing ovarian stimulation for in vitro fertilization[J].Horm Metab Res,2019,51(5):315-325.DOI:10.1055/a-0893-3122.
[16] Bornstein SR,Allolio B,Arlt W,et al.Diagnosis and treatment of primary adrenal insufficiency:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(2):364-389.DOI:10.1210/jc.2015-1710.
[17] Ryu RJ,Easterling TR,Caritis SN,et al.Prednisone pharmacokinetics during pregnancy and lactation[J].J Clin Pharmacol,2018,58(9):1223-1232.DOI:10.1002/jcph.1122.
[18] Nowotny H,Ahmed SF,Bensing S,et al.Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis[J].Endocrine,2021,71(3):586-594.DOI:10.1007/s12020-021-02649-6.
[19] 李娟,王秀敏.先天性肾上腺皮质增生症的诊治与管理[J].中华全科医师杂志,2023,22(6):574-579.DOI:10.3760/cma.j.cn114798-20230216-00134.